Fig. 3From: Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysisMeta-analysis results. Prevalence of patient-led treatment non-persistence among the patients on anti-VEGF therapy and subgroup analysis within 1Â year of non-persistence to the prescribed anti-VEGF therapy according to duration. The overall prevalence of non-persistence at this time point is 0.3 (i.e., 30%)Back to article page